LIVZON PHARMA (01513) appointed Liu Daping as president.

LIVZON PHARMA (01513) announced that on February 28, 2026, they received written resignations from Mr. Xu Guoxiang and Mr. Tao Desheng. Mr. Xu resigned voluntarily from his positions as an executive director, vice chairman, and vice president of the company upon reaching retirement age and will not hold any positions in the company, its subsidiaries, or affiliated companies after his resignation. Mr. Tao also resigned voluntarily from his positions as a non-executive director, vice chairman, member of the company's board nomination committee, and member of the strategic committee upon reaching retirement age and will also not hold any positions in the company, its subsidiaries, or affiliated companies after his resignation. Their resignations are effective from the date they were submitted to the board of directors (February 28, 2026). The company also received written resignations from Mr. Tang Yanggang and Ms. Si Yanxia on February 28, 2026. Due to job adjustments, Mr. Tang voluntarily resigned from his position as the company's president but will continue to serve as an executive director in the company, as well as holding positions in its subsidiaries and affiliated companies. Ms. Si voluntarily resigned from her position as vice president and CFO of the company, as well as all other positions within the company and its subsidiaries, due to reaching retirement age. Their resignations are effective from the date they were submitted to the board of directors (February 28, 2026). After review and approval by the board nomination committee, the board of directors agreed to nominate Mr. Liu Daping as a candidate for executive director of the company's 11th board of directors, with a term starting from the date of shareholder approval until the end of the 11th board of directors term, subject to approval at the company's shareholders' meeting. The board also agreed to appoint Mr. Liu as the company's president, with an official start date of February 28, 2026, until the end of the 11th board of directors term. Mr. Tang, the company's executive director, was appointed as vice chairman of the company's 11th board of directors, with a term starting on February 28, 2026, until the end of the 11th board of directors term and is eligible for re-election. Mr. Wang Sheng was appointed as the company's CFO, with an official start date of February 28, 2026, until the end of the 11th board of directors term. Mr. Chen Zhihua was appointed as the company's vice president, with an official start date of February 28, 2026, until the end of the 11th board of directors term. The company's authorized representative under Rule 3.05 of the Listing Rules of the Hong Kong Stock Exchange has been changed from Mr. Tang to Mr. Liu, effective from the date of Mr. Liu's appointment as executive director, subject to approval at the company's shareholders' meeting.